Dr Rachel Harding
Editor-in-chief
Toronto, Canada
Rachel Harding is an Assistant Professor at the Department of Pharmacology and Toxicology and a Principal Investigator at the Structural Genomics Consortium. Rachel completed her undergraduate and DPhil in structural biology at the University of Oxford, before moving to the University of Toronto for her postdoctoral training. A key focus of Rachel’s research is the huntingtin protein, mutated in people with Huntington’s disease. Huntington’s is a devastating, incurable, genetic, neurodegenerative disease caused by a CAG-tract expansion in the Huntingtin gene. Rachel studies the structure-function of the huntingtin protein in both its wildtype and disease forms, with a view to better understand the mechanisms of disease, as well as trying to find new avenues of therapeutic intervention.
Articles edited by Dr Rachel Harding
- Announcing the 2024 HDBuzz Prize for Young Science Writers!
- HDBuzz needs your help
- Hope vs. hype: seeking truth in recent Prilenia headlines
- Mini brains grown in a dish shed light on Huntington’s disease and how we might treat it
- Steady progress from uniQure - promising data to end the year
- Hereditary Disease Foundation (HDF) conference 2024 – Day 4
- Hereditary Disease Foundation (HDF) conference 2024 – Day 3
- Hereditary Disease Foundation (HDF) conference 2024 – Day 2
- Blue skies for Skyhawk: Positive news from Phase 1 trial for SKY-0515
- No pivot needed for PTC-518
- Two birds, one stone: HTT-lowering drugs also target CAG expansions
- Hats off to brain donors on Brain Donation Awareness Day
- A sprinkling of good news for the treatment of HD chorea
- A new era for HDBuzz
- The director’s cut: how CAG repeats change the editing of genetic messages
- Making babies: having a family, the HD way
- Huntington's Disease Therapeutics Conference 2024 - Day 3
- Huntington's Disease Therapeutics Conference 2024 - Day 2
- Huntington's Disease Therapeutics Conference 2024 - Day 1
- CRISPR-based drugs: one giant leap for mankind
- Putting it in print: GENERATION HD1 study results published
- Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
- Drug to treat movement symptoms of HD approved by FDA
- PROOF-HD study of pridopidine ends with negative result
- Hunting for balance: how the huntingtin protein compensates in HD
- uniQure gets the green light to resume testing HD gene therapy
- Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Updates from uniQure about their gene therapy for Huntington's disease
- Revisiting vitamin therapy for HD
- Oral drug may change the story for huntingtin lowering
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
- Huntington's disease therapeutics conference 2021 - Day 3
- Huntington's disease therapeutics conference 2021 - Day 2
- Huntington’s disease therapeutics conference 2021 - Day 1
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Uncovering the dark side of DNA repair to design HD treatments
- When genes are unstable: targeting somatic instability in HD
- What does COVID-19 mean for Huntington’s disease families and HD research?
- New molecule can reverse the Huntington's disease mutation in lab models
Articles written by Dr Rachel Harding
- Bringing HD Treatments to Market: The Role of Regulatory Oversight
- Buckle in: Gene therapy AMT-130 appears to slow down signs of Huntington’s disease in Phase I/II clinical trial
- Hereditary Disease Foundation (HDF) conference 2024 – Day 4
- Hereditary Disease Foundation (HDF) conference 2024 – Day 3
- Hereditary Disease Foundation (HDF) conference 2024 – Day 2
- Hereditary Disease Foundation (HDF) conference 2024 – Day 1
- Positive news from Wave Life Sciences SELECT-HD trial
- A new era for HDBuzz
- Understanding expansions at the single cell level
- Huntington's Disease Therapeutics Conference 2024 - Day 3
- Huntington's Disease Therapeutics Conference 2024 - Day 2
- Huntington's Disease Therapeutics Conference 2024 - Day 1
- Putting it in print: GENERATION HD1 study results published
- Getting to the Root of Huntington's Disease: A Plant-Based Approach
- Tipping the balance; new insights into HD genetic modifiers
- Drug to treat movement symptoms of HD approved by FDA
- Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
- Start here!
- Huntington’s disease therapeutics conference 2023 - Day 3
- Huntington’s disease therapeutics conference 2023 - Day 2
- Huntington’s disease therapeutics conference 2023 - Day 1
- Roche Phase II GENERATION HD2 study underway
- Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
- Update on the PTC Therapeutics PIVOT-HD Trial
- Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
- Hereditary Disease Foundation (HDF) conference 2022 – Day 4
- Hereditary Disease Foundation (HDF) conference 2022 – Day 3
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Updates from uniQure about their gene therapy for Huntington's disease
- Huntington’s disease therapeutics conference 2022 - Day 2
- Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
- Huntington’s disease therapeutics conference 2022 - Day 1
- A spoonful of branaplam helps the huntingtin go down
- Huntington’s disease therapeutics conference 2022 - Day 3
- Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- “Seeing” the toxic huntingtin protein in people with HD
- Updates from the EHDN Meeting 2021
- Does blood hold the key to testing treatments earlier in HD patients?
- Scientists identify precisely how pridopidine works in models of Huntington’s disease
- Huntington's disease therapeutics conference 2021 - Day 3
- Huntington’s disease therapeutics conference 2021 - Day 1
- Huntington's disease therapeutics conference 2021 - Day 2
- Huntington’s disease clinical trial round up
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Sad News from Roche and Ionis - ASO Trial Halted Early
- Vaccines and HD
- GPR52: Exploring a new way to lower huntingtin
- Updates from the EHDN Plenary Meeting 2020
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
- Treatment for neurological disorder could be repurposed for Huntington’s disease patients
- When genes are unstable: targeting somatic instability in HD
- Caution urged for the use of gene-editing technology CRISPR
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
- Huntington’s disease therapeutics conference 2020 - Day 1
- Huntington’s disease therapeutics conference 2020 - Day 3
- Huntington’s disease therapeutics conference 2020 - Day 2
- Screening the entire genome for new drug targets for HD